[Click eStock] "Aliglo Gains Traction in US... GC Pharma Signals Profit Growth"

On September 19, IBK Investment & Securities stated that GC Pharma is expected to achieve improved profitability this year, driven by the successful entry of its flagship product, Aliglo, into the US market. The firm maintained a buy rating and set a target price of 190,000 won.

Jung Isu, a researcher at IBK Investment & Securities, analyzed, "Aliglo, a treatment for congenital immunodeficiency, is expected to achieve its initial annual sales target of 100 million dollars in the US market in 2025."

Jung explained, "Aliglo, which was launched in the US market in August 2024, surpassed cumulative sales of 100 billion won within a year, and quarterly sales continue to grow. If the target sales are achieved, the operating margin will reach 20 percent, which is expected to contribute to profit growth in 2025."

Jung estimated that GC Pharma's sales in 2025 will increase by 10.6 percent year-on-year to 1.8584 trillion won, while operating profit will surge by 117.1 percent to 69.7 billion won during the same period. He added, "In 2025, the full-year contribution from high-margin Aliglo sales, along with reduced losses from subsidiaries GC Cell and ABO Holdings, will enable stable sales growth and improvement in operating margin (from 1.9 percent to 3.8 percent)."

The firm maintained a buy rating and set a target price of 190,000 won. Jung commented, "We applied a multiple of 17 times. This multiple reflects the level of expectations at the time of Aliglo's US launch, and we anticipate that expectations for achieving mid- to long-term targets will increase further as Aliglo becomes firmly established in the US market."

This content was produced with the assistance of AI translation services.